monoclonal antibody

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.

Chemomab Therapeutics achieved FDA End-of-Phase 2 approval for nebokitug in PSC treatment, establishing streamlined regulatory pathway with promising Phase 2 data.

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.